Table 2: Major studies of CSF biomarker to predict progression from MCI to AD published between 2004 and 2010.

StudyYearCaseFollow-upMCI to ADMarkerSensitivitySpecificityOther

Hampel200452 MCI
93 AD
10 cont
8.4 M29/52 (56%)Aβ42, TauAβ42 59%
Tau 83%
Aβ42 100%
Tau 90%
European cohort

Parnetti200655 MCI
100 AD
14 DLB
11 FTD
1 Y11/55 (20%)
38% of MCI has 2 marker abnormalities
Aβ42, Tau, pTau1812 biomarker abnormality
in AD converters (91%)
Normal markers in stable MCI (88%)Mayo Clinic Cohort

Hansson2006137 MCI
39 cont
4~7 Y57 AD (42%)
21 nonAD dementia (15%)
56 stable MCI (41%)
Aβ42, Tau, pTau181Aβ42/Tau 95%
Aβ42/Tau/
pTau181 95%
Aβ42/Tau 83%
Aβ42/Tau/
pTau181 87%
Prospective study

Show2009100 AD
191 MCI
114 cont
1 Y37/191 (19%)Aβ42, Tau, pTau181 Tau/Aβ42 predicted 89% of AD converters
CSF Aβ42 highly correlated with brain pathology
US-ADNI

Mattsson2009750 MCI
529 AD
304 cont
>2 Y271 AD/750 MCI (36%)
59 nonAD
dementia/750 MCI
Aβ42,
Tau,
pTau181
83%73%12 centers
Europe/US

Visser200960 SCI
37 naMCI
71 aMCI
89 cont
3 Y8/22 CSF/AD naMCI (36%)
27/53 CSF/AD aMCI (51%)
Aβ42, Tau, pTau181 CSF/AD was observed in control 31%, SCI 52%, naMCI 68%, aMCI 79%
All AD had CSF/AD
CSF/AD is a significant risk in aMCI
DESCRIPA study
Europe study

SCI: subjective cognitive impairment; naMCI: nonamnesctic MCI; aMCI: amnestic MCI; CSF/AD: CSF AD profile (decreased Aβ42/increased tau).